Find out all you need to know about Herceptin (trastuzumab) for early and more advanced HER2-positive breast cancer, including what to expect, outcomes, side effects, and more.

Answer: Herceptin is a drug, an agent whose chemical name is 'trastuzumab.' It's a monoclonal antibody that interferes with the function of an important protein in some breast cancers: the HER2 ...

According to the FDA decision, announced yesterday, Herceptin may now be used in combination with other cancer drugs to treat HER2 positive breast cancer after surgery — either lumpectomy, which ...

New research finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative – and that the drug Herceptin, which targets HER2, may have ...

In 1998, Herceptin (trastuzumab), the first medication to directly target HER2, was approved by the FDA. Oncologists usually start with this drug before trying other treatments.

The breast cancer drug Herceptin prevents breast cancer from coming back in some women, new research shows. Moreover, Herceptin works just as well with and without Adriamycin, a chemotherapy drug ...

Medical community recognise significance of Herceptin® results in early HER2-positive breast cancer Landmark adjuvant breast cancer trial published in New England Journal of Medicine ...

Adding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according ...

Herceptin could beat HER2-positive breast cancer in many of the 250,000 women diagnosed with the disease around the world each year. Genentech, the maker of Herceptin, filed for additional approval of ...

“Since Herceptin’s approval in HER2-positive advanced breast cancer more than a decade ago, we have continued to study how the HER2 pathway contributes to the growth and spread of other ...

HER2 is short for human epidermal growth factor receptor 2. Researchers discovered HER2 breast cancer in the 1980s. Too many copies of the HER2 gene or its overexpression appeared to cause an ...

Genentech announced that Herceptin (trastuzumab) has been approved in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic ...